276 related articles for article (PubMed ID: 32126270)
21. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation.
Wang C; Terrigno M; Li J; Distler T; Pandya NJ; Ebeling M; Tyanova S; Hoozemans JJM; Dijkstra AA; Fuchs L; Xiang S; Bonni A; Grüninger F; Jagasia R
Neuron; 2023 Sep; 111(17):2660-2674.e9. PubMed ID: 37385246
[TBL] [Abstract][Full Text] [Related]
22. Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies.
Limorenko G; Lashuel HA
Chem Soc Rev; 2022 Jan; 51(2):513-565. PubMed ID: 34889934
[TBL] [Abstract][Full Text] [Related]
23. Roles of tau protein in health and disease.
Guo T; Noble W; Hanger DP
Acta Neuropathol; 2017 May; 133(5):665-704. PubMed ID: 28386764
[TBL] [Abstract][Full Text] [Related]
24. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
25. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic strategies for tauopathies and drug repurposing as a potential approach.
Islam M; Shen F; Regmi D; Du D
Biochem Pharmacol; 2022 Apr; 198():114979. PubMed ID: 35219701
[TBL] [Abstract][Full Text] [Related]
27. TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease.
Zhang ZY; Harischandra DS; Wang R; Ghaisas S; Zhao JY; McMonagle TP; Zhu G; Lacuarta KD; Song J; Trojanowski JQ; Xu H; Lee VM; Yang X
Science; 2023 Jul; 381(6656):eadd6696. PubMed ID: 37499037
[TBL] [Abstract][Full Text] [Related]
28. The role of tau phosphorylation and cleavage in neuronal cell death.
Chun W; Johnson GV
Front Biosci; 2007 Jan; 12():733-56. PubMed ID: 17127334
[TBL] [Abstract][Full Text] [Related]
29. Tau-mediated dysregulation of RNA: Evidence for a common molecular mechanism of toxicity in frontotemporal dementia and other tauopathies.
Koren SA; Galvis-Escobar S; Abisambra JF
Neurobiol Dis; 2020 Jul; 141():104939. PubMed ID: 32413399
[TBL] [Abstract][Full Text] [Related]
30. Post-translational modifications of tau protein in Alzheimer's disease.
Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
J Neural Transm (Vienna); 2005 Jun; 112(6):813-38. PubMed ID: 15517432
[TBL] [Abstract][Full Text] [Related]
31. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways.
El Fatimy R; Li S; Chen Z; Mushannen T; Gongala S; Wei Z; Balu DT; Rabinovsky R; Cantlon A; Elkhal A; Selkoe DJ; Sonntag KC; Walsh DM; Krichevsky AM
Acta Neuropathol; 2018 Oct; 136(4):537-555. PubMed ID: 29982852
[TBL] [Abstract][Full Text] [Related]
33. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
34. Brief update on different roles of tau in neurodegeneration.
Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
[TBL] [Abstract][Full Text] [Related]
35. Tau/DDX6 interaction increases microRNA activity.
Chauderlier A; Gilles M; Spolcova A; Caillierez R; Chwastyniak M; Kress M; Drobecq H; Bonnefoy E; Pinet F; Weil D; Buée L; Galas MC; Lefebvre B
Biochim Biophys Acta Gene Regul Mech; 2018 Aug; 1861(8):762-772. PubMed ID: 29966762
[TBL] [Abstract][Full Text] [Related]
36. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
37. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
Hasegawa M
Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
[TBL] [Abstract][Full Text] [Related]
38. Post-translational modifications of tau protein: implications for Alzheimer's disease.
Martin L; Latypova X; Terro F
Neurochem Int; 2011 Mar; 58(4):458-71. PubMed ID: 21215781
[TBL] [Abstract][Full Text] [Related]
39. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
Marcus JN; Schachter J
J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
[TBL] [Abstract][Full Text] [Related]
40. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
